Victory Capital Management
IRWD icon

Victory Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Victory Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.69M Buy
678,713
+20,256
+3% +$84.6K ﹤0.01% 1574
2026
Q2 		$2.77M Sell
658,457
-54,730
-8% -$211K ﹤0.01% 1544
2026
Q1 		$2.5M Buy
713,187
+695,145
+3,853% +$2.85M ﹤0.01% 1538
2025
Q4 		$60.8K Buy
18,042
+37
+0.2% +$96 ﹤0.01% 2314
2025
Q3 		$23.6K Sell
18,005
-614
-3% -$635 ﹤0.01% 2389
2025
Q2 		$13.4K Sell
18,619
-95
-0.5% -$75 ﹤0.01% 2465
2025
Q1 		$27.5K Sell
18,714
-194,578
-91% -$463K ﹤0.01% 2411
2024
Q4 		$945K Sell
213,292
-4,717
-2% -$19.1K ﹤0.01% 1836
2024
Q3 		$898K Sell
218,009
-4,564
-2% -$24.5K ﹤0.01% 1822
2024
Q2 		$1.45M Buy
222,573
+94,882
+74% +$671K ﹤0.01% 1547
2024
Q1 		$1.11M Sell
127,691
-4,096,892
-97% -$49.7M ﹤0.01% 1693
2023
Q4 		$48.3M Sell
4,224,583
-182,149
-4% -$1.8M 0.05% 448
2023
Q3 		$42.4M Buy
4,406,732
+668,694
+18% +$6.55M 0.05% 460
2023
Q2 		$39.8M Buy
3,738,038
+707,706
+23% +$7.61M 0.04% 500
2023
Q1 		$31.9M Buy
3,030,332
+127,656
+4% +$1.43M 0.04% 609
2022
Q4 		$36M Buy
2,902,676
+845
+0% +$9.6K 0.04% 574
2022
Q3 		$30.1M Buy
2,901,831
+2,738,889
+1,681% +$31.1M 0.04% 645
2022
Q2 		$1.88M Sell
162,942
-12,046
-7% -$142K ﹤0.01% 1483
2022
Q1 		$2.1M Buy
174,988
+17,017
+11% +$195K ﹤0.01% 1484
2021
Q4 		$1.84M Buy
157,971
+81,084
+105% +$995K ﹤0.01% 1581
2021
Q3 		$1M Buy
76,887
+25,378
+49% +$328K ﹤0.01% 1863
2021
Q2 		$663K Buy
51,509
+2,881
+6% +$33K ﹤0.01% 2059
2021
Q1 		$544K Buy
48,628
+6,625
+16% +$70K ﹤0.01% 2165
2020
Q4 		$478K Buy
42,003
+9,298
+28% +$102K ﹤0.01% 2104
2020
Q3 		$294K Buy
32,705
+12,607
+63% +$125K ﹤0.01% 2169
2020
Q2 		$207K Sell
20,098
-182
-0.9% -$1.86K ﹤0.01% 2291
2020
Q1 		$205K Sell
20,280
-5,812
-22% -$68.3K ﹤0.01% 2143
2019
Q4 		$347K Buy
26,092
+4,516
+21% +$49.8K ﹤0.01% 2157
2019
Q3 		$185K Buy
+21,576
New +$210K ﹤0.01% 2243

Other funds holding IRWD

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Ritholtz Wealth Management
Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
CWA Asset Management Group
CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return
IEQ Capital
IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return

Victory Capital Management's IRWD Position: Q3 2026 in Review

Victory Capital Management increased its Ironwood Pharmaceuticals (IRWD) stake by 3.1% in Q3 2026, buying an estimated $84.6K and bringing the position to 678,713 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Victory Capital Management first reported a position in IRWD in Q3 2019 and has held it in 29 quarters since. The position peaked at $48.3M in Q4 2023. 112 funds tracked by Wall St. Rank hold IRWD as of Q3 2026.

  • Victory Capital Management held 678,713 shares of Ironwood Pharmaceuticals worth $2.69M as of Q3 2026.
  • Victory Capital Management bought 20,256 Ironwood Pharmaceuticals shares in Q3 2026, an estimated $84.6K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q3 2026, its #1574 holding.
  • Victory Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2019 and has held it in 29 quarters since.
  • Victory Capital Management's Ironwood Pharmaceuticals position peaked at $48.3M in Q4 2023.
  • 112 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.